TITLE

Sustiva Once-Daily Anti-HIV Capsules Approved In Europe

PUB. DATE
July 1999
SOURCE
Worldwide Biotech;Jul99, Vol. 11 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on DuPont Pharmaceuticals Incorporated's anti-HIV drug, Sustiva. Its therapeutic concern and evidence of effectiveness; Its approval and recommendation; Information on Sustiva therapy; Side effects.
ACCESSION #
2107045

 

Related Articles

  • DuPont receives FDA approval for anti-HIV drug.  // Chemical Market Reporter;09/28/98, Vol. 254 Issue 13, p14 

    Reports on DuPont Pharmaceuticals' receipt of an approval from the United States Food and Drug Administration for its anti-HIV drug product.

  • Product news.  // Medical Marketing & Media;Nov98, Vol. 33 Issue 11, p30 

    Reports on the approval made by the United States Food and Drug Administration for DuPont Pharmaceutical's Sustiva to treat HIV and AIDS in children and adults.

  • AIDS drug gets quick OK.  // FDA Consumer;Jan/Feb99, Vol. 33 Issue 1, p2 

    Reports on the approval of efavirenz, manufactured under the trade name Sustiva by DuPont Pharmaceuticals, for the treatment of HIV-1 infection in combination with other HIV drugs. Symptoms that were reported in more than half of patients treated with efavirenz; Need to monitor patients'...

  • Combo affirmed. Horton, Kathleen // Pharmaceutical Executive;Jul97, Vol. 17 Issue 7, p96 

    Reports on the positive results of Dupont Merck's Phase II clinical trials to study the effectiveness of its DMP 266 in combination with Crixivan (indinavir) for HIV infections.

  • Expanded access for Efavirenz.  // AIDS Patient Care & STDs;Dec97, Vol. 11 Issue 6, p457 

    Announces an expanded access program for the antiviral agent, efavirenz (Sustiva, formerly DMP 266) by DuPont Merck. Who use program as of April 1998; Minimum age for participants in program; Exclusions in the program.

  • Contract pricing holds.  // Drug Topics;12/12/94, Vol. 138 Issue 23, p7 

    Reports on the reaction of hospital registered pharmacists on the plan of DuPont Pharma to reintroduce Coumadin, Percocet and Percodan in unit dose. Original plan of the company to phase out the drugs; Prices of the drugs.

  • Prescription drugs filled, labeled in sync. Abrams, Bernard // Packaging Digest;Sep2000, Vol. 37 Issue 10, p42 

    Reports on DuPont Pharmaceuticals' installation of a versatile packaging line at its Garden City, New York operation. Number of prescription drug bottles processed per minute; Performance and prospects for the line; Key considerations in selecting and modifying the equipment; Packaging process.

  • Dupont Group continues expanding. Ruano, Lida Estela // Caribbean Business;2/12/1998, Vol. 26 Issue 6, p8 

    Reports that DuPont-Merck Pharma company and the Swiss Ares-Serona Group manufacturing contract, is enjoying success for the third year, while focusing on the construction of a state of the art building in Puerto Rico, as the company continues to expand. Economic aspects of the project; When...

  • Equivalence, equity & exclusivity. Wechsler, Jill // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p16 

    Focuses on the controversy over the equivalence of narrow therapeutic index (NTI) generics in the United States. Debate over DuPont Merck's link with patient and medical groups to promote adoption of patient notification and consent legislation; Concerns on the antigeneric campaign in the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics